Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.41 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | WRN | Q14191 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 2/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10030440 | 0.86 | DYRK1A (0.39) | HIPK2CSNK2A2CSNK2BBLMWRN | |
| SCHEMBL10030467 | 0.85 | HTR5A (0.48) | HIPK2 | |
| SCHEMBL10030418 | 0.82 | HTR5A (0.38) | SLC22A12 | |
| SCHEMBL9907485 | 0.72 | HTR5A (0.49) | SLC22A12XDH | |
| SCHEMBL30771577 | 0.70 | HIPK2 (0.77) | HIPK2CSNK2A2CSNK2B | |
| SCHEMBL20718403 | 0.70 | HIPK2 (0.77) | HIPK2CSNK2A2CSNK2B | |
| SCHEMBL10063768 | 0.70 | SLC22A12 (0.45) | HIPK2CSNK2A2CSNK2BSLC22A12XDH | |
| SCHEMBL28442922 | 0.69 | HIPK2 (0.75) | HIPK2CSNK2A2CSNK2B | |
| SCHEMBL10063756 | 0.68 | SLC22A12 (0.48) | CSNK2A2CSNK2BSLC22A12 | |
| SCHEMBL393075 | 0.68 | S1PR3 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | ASTELLAS PHARMA INC. (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041036-A1 | SUBSTITUTED ACYLGUANIDINE DERIVATIVES (AS AMENDED) | HTR5A, HTR2A, HTR1A | HIPK2 2763/4885IP6K1 4417/4885IP6K3 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.